2 Minutes with Joey - REGN Stock News

Two minutes with Joey on Regeneron Pharmaceuticals (REGN) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.

2 Minutes with Joey - REGN Stock News is a general podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts 2 Minutes with Joey - REGN Stock News, a general show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  2 Minutes with Joey - REGN Stock News

  REGN Today - Aug 06: Profit Slip Amid Trials

  Aug 6, 20262 minS0

  Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about Regeneron Pharmaceuticals, or REGN, which had a bit of a rough day. It dropped just under half a percent—yeah, that one stung.<br /><br />So, what went down? REGN started off kinda steady but ended up getting smoked a bit. It closed down after some mixed news about their earnings and clinical trials. You know how it goes—people get jittery, and when that happens, they hit the sell button fast.<br /><br />Now, why did th...

  ListenShow Notes
• 

  2 Minutes with Joey - REGN Stock News

  REGN Today - Aug 05: Clinical Trials Cause Concern

  Aug 5, 20261 minS0

  Hey there! It’s Joey, your friendly longtime investor, and I’m here to break down what happened with Regeneron Pharmaceuticals today. So, REGN had a bit of a mixed bag day, closing up about 1.75%. Not too shabby, but still a bit of a rollercoaster.<br /><br />So, what went down? Well, shares were sold off by MassMutual Private Wealth & Trust. That always raises some eyebrows, ya know? Plus, there’s been chatter about Regeneron’s clinical trials. Apparently, some results didn’t live up to the hype, which caused a bit of a stir. I mean, when clinical trials go sideway...

  ListenShow Notes
• 

  2 Minutes with Joey - REGN Stock News

  REGN Today - Aug 04: Mixed Signals in Earnings

  Aug 4, 20261 minS0

  Hey there! It's Joey here, your friendly long-time investor, breaking down the day. Today we’re talking about Regeneron Pharmaceuticals. It was a bit of a red day for them, down just a tad—like 0.4%. <br /><br />So, what happened? Well, the stock kinda hung around the same spot, barely moving at all. It’s been a wild ride lately; they had seven green days in a row before this little dip. That’s a solid climb of about 17% over that time. But today? Just a slight pullback. <br /><br />Now, why’d it happen? There’s some chatter out there. Regen...

  ListenShow Notes
• 

  2 Minutes with Joey - REGN Stock News

  REGN Today - Aug 03: Strong Earnings Drive Momentum

  Aug 3, 20262 minS0

  Hey there! It's Joey, your friendly neighborhood investor, here to break down what went down with Regeneron Pharmaceuticals today. So, REGN had a bit of a green day, up about half a percent. Not a massive jump, but hey, it's been a solid run lately.<br /><br />Now, here’s the scoop. Regeneron has been on a roll—seven green days in a row! That’s a pretty sweet streak, with the stock climbing around 17% recently. The buzz today was mainly about their Q2 earnings. They posted some strong revenue numbers, and their EYLEA HD treatment even outsold the regular EYLEA...

  ListenShow Notes
• 

  2 Minutes with Joey - REGN Stock News

  REGN Today - Aug 02: Margin Squeeze and Class Action

  Aug 2, 20262 minS0

  Hey there! It’s Joey, your friendly stock guy, and I’ve been investing for years. Today, we’re talking about Regeneron Pharmaceuticals, and it was a green day, up about 3.3%. Not too shabby!<br /><br />So, what went down? REGN had a decent day, climbing up after a bit of a rollercoaster lately. The stock’s been swinging around, but today it found some footing. Volume was pretty average, so nothing too wild on that front.<br /><br />Now, why the move? Well, it looks like there’s a lot happening behind the scenes. On one hand, Regeneron reported some solid...

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.